Mucopolysaccharidosis Type Vi
📧 Sign up to get email alerts when something new happens for Mucopolysaccharidosis Type Vi.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2024-12-16EMA Authorised: Naglazyme (galsulfase) — BioMarin International Limited
The European Medicines Agency authorised Naglazyme (galsulfase) by BioMarin International Limited for treating mucopolysaccharidosis type VI…
-
FDA approval · 2019-12-17FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)
FDA approved a supplemental application for Naglazyme (galsulfase) from BioMarin Pharmaceutical Inc. The notice indicates regulatory approva…
-
FDA approval · 2013-03-26FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)
The FDA approved a supplemental application for Naglazyme (galsulfase) from BioMarin Pharmaceutical Inc.
-
FDA approval · 2011-04-28FDA Approved: NAGLAZYME — Supplemental Application (BioMarin Pharmaceutical Inc.)
The FDA approved a supplemental Biologics License Application for Naglazyme (galsulfase) by BioMarin Pharmaceutical Inc., updating the label…